This afternoon we watched Sarepta Therapeutics rise 3.5% to a price of $111.81 per share. The mid-cap Pharmaceutical company is now trading -36.81% below its average target price of $176.94. Analysts have set target prices ranging from $139.0 to $223.0 per share for Sarepta Therapeutics, and have given the stock an average rating of buy.
Sarepta Therapeutics's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 5.0%. The stock's short ratio is 4.75. The company's insiders own 4.25% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 88.1%. In conclusion, we believe there is positive market sentiment regarding Sarepta Therapeutics.
Institutions Invested in Sarepta Therapeutics
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-03-31 | Vanguard Group Inc | 9% | 8,112,964 | $907,110,485 |
| 2023-06-30 | Blackrock Inc. | 6% | 5,503,466 | $615,342,520 |
| 2023-03-31 | Janus Henderson Group PLC | 6% | 4,908,204 | $548,786,277 |
| 2023-06-30 | JP Morgan Chase & Company | 5% | 4,404,093 | $492,421,627 |
| 2023-03-31 | Avoro Capital Advisors LLC | 4% | 3,650,000 | $408,106,491 |
| 2023-03-31 | EcoR1 Capital, LLC | 3% | 2,999,453 | $335,368,832 |
| 2023-03-31 | Wellington Management Group, LLP | 3% | 2,933,612 | $328,007,150 |
| 2023-06-30 | Bank Of New York Mellon Corporation | 3% | 2,432,768 | $272,007,784 |
| 2023-06-30 | FMR, LLC | 2% | 1,803,828 | $201,686,004 |
| 2023-03-31 | State Street Corporation | 2% | 1,773,976 | $198,348,252 |
